Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The Effect of 4-Methylcatechol on Platelets in Familial Hypercholesterolemic Patients Treated with Lipid Apheresis and/or Proprotein Convertase Subtilisin Kexin 9 Monoclonal Antibodies

L. Konečný, M. Hrubša, J. Karlíčková, A. Carazo, L. Javorská, K. Matoušová, LK. Krčmová, A. Šmahelová, V. Blaha, M. Bláha, P. Mladěnka

. 2023 ; 15 (8) : . [pub] 20230411

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23010454

Grant support
NU21-02-00135 Czech Health Research Council
SVV 260 549 Charles University
UHHK, 00179906 MH CZ - DRO

Elevated low-density lipoprotein (LDL) cholesterol levels lead to atherosclerosis and platelet hyperaggregability, both of which are known culprits of arterial thrombosis. Normalization of LDL cholesterol in familial hypercholesterolemia (FH) is not an easy task and frequently requires specific treatment, such as regularly performed lipid apheresis and/or novel drugs such as proprotein convertase subtilisin kexin 9 monoclonal antibodies (PCSK9Ab). Moreover, a high resistance rate to the first-line antiplatelet drug acetylsalicylic acid (ASA) stimulated research of novel antiplatelet drugs. 4-methylcatechol (4-MC), a known metabolite of several dietary flavonoids, may be a suitable candidate. The aim of this study was to analyse the antiplatelet effect of 4-MC in FH patients and to compare its impact on two FH treatment modalities via whole-blood impedance aggregometry. When compared to age-matched, generally healthy controls, the antiplatelet effect of 4-MC against collagen-induced aggregation was higher in FH patients. Apheresis itself improved the effect of 4-MC on platelet aggregation and blood from patients treated with this procedure and pretreated with 4-MC had lower platelet aggregability when compared to those solely treated with PCKS9Ab. Although this study had some inherent limitations, e.g., a low number of patients and possible impact of administered drugs, it confirmed the suitability of 4-MC as a promising antiplatelet agent and also demonstrated the effect of 4-MC in patients with a genetic metabolic disease for the first time.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010454
003      
CZ-PrNML
005      
20230801132434.0
007      
ta
008      
230718s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/nu15081842 $2 doi
035    __
$a (PubMed)37111061
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Konečný, Lukáš $u The Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, 50005 Hradec Králové, Czech Republic
245    14
$a The Effect of 4-Methylcatechol on Platelets in Familial Hypercholesterolemic Patients Treated with Lipid Apheresis and/or Proprotein Convertase Subtilisin Kexin 9 Monoclonal Antibodies / $c L. Konečný, M. Hrubša, J. Karlíčková, A. Carazo, L. Javorská, K. Matoušová, LK. Krčmová, A. Šmahelová, V. Blaha, M. Bláha, P. Mladěnka
520    9_
$a Elevated low-density lipoprotein (LDL) cholesterol levels lead to atherosclerosis and platelet hyperaggregability, both of which are known culprits of arterial thrombosis. Normalization of LDL cholesterol in familial hypercholesterolemia (FH) is not an easy task and frequently requires specific treatment, such as regularly performed lipid apheresis and/or novel drugs such as proprotein convertase subtilisin kexin 9 monoclonal antibodies (PCSK9Ab). Moreover, a high resistance rate to the first-line antiplatelet drug acetylsalicylic acid (ASA) stimulated research of novel antiplatelet drugs. 4-methylcatechol (4-MC), a known metabolite of several dietary flavonoids, may be a suitable candidate. The aim of this study was to analyse the antiplatelet effect of 4-MC in FH patients and to compare its impact on two FH treatment modalities via whole-blood impedance aggregometry. When compared to age-matched, generally healthy controls, the antiplatelet effect of 4-MC against collagen-induced aggregation was higher in FH patients. Apheresis itself improved the effect of 4-MC on platelet aggregation and blood from patients treated with this procedure and pretreated with 4-MC had lower platelet aggregability when compared to those solely treated with PCKS9Ab. Although this study had some inherent limitations, e.g., a low number of patients and possible impact of administered drugs, it confirmed the suitability of 4-MC as a promising antiplatelet agent and also demonstrated the effect of 4-MC in patients with a genetic metabolic disease for the first time.
650    _2
$a lidé $7 D006801
650    _2
$a monoklonální protilátky $x farmakologie $x terapeutické užití $7 D000911
650    _2
$a subtilisin $7 D020860
650    _2
$a proproteinkonvertasa subtilisin/kexin typu 9 $7 D000071449
650    _2
$a proproteinkonvertasy $x terapeutické užití $7 D043484
650    12
$a hyperlipoproteinemie typ II $x farmakoterapie $7 D006938
650    _2
$a LDL-cholesterol $7 D008078
650    12
$a separace krevních složek $x metody $7 D001781
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hrubša, Marcel $u The Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, 50005 Hradec Králové, Czech Republic $1 https://orcid.org/0000000299589366
700    1_
$a Karlíčková, Jana $u The Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové, Charles University, 50005 Hradec Králové, Czech Republic
700    1_
$a Carazo, Alejandro $u The Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, 50005 Hradec Králové, Czech Republic $1 https://orcid.org/0000000236047981 $7 uk20201095192
700    1_
$a Javorská, Lenka $u The Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, 50005 Hradec Králové, Czech Republic
700    1_
$a Matoušová, Kateřina $u The Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, 50005 Hradec Králové, Czech Republic $1 https://orcid.org/0000000182835770
700    1_
$a Krčmová, Lenka Kujovská $u The Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, 50005 Hradec Králové, Czech Republic
700    1_
$a Šmahelová, Alena $u The 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, 50005 Hradec Králové, Czech Republic
700    1_
$a Blaha, Vladimír $u The 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, 50005 Hradec Králové, Czech Republic $1 https://orcid.org/0000000180889919 $7 xx0002944
700    1_
$a Bláha, Milan $u The 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, 50005 Hradec Králové, Czech Republic
700    1_
$a Mladěnka, Přemysl $u The Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, 50005 Hradec Králové, Czech Republic $1 https://orcid.org/0000000260766900 $7 xx0233006
773    0_
$w MED00189563 $t Nutrients $x 2072-6643 $g Roč. 15, č. 8 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37111061 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132430 $b ABA008
999    __
$a ok $b bmc $g 1963086 $s 1196719
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 15 $c 8 $e 20230411 $i 2072-6643 $m Nutrients $n Nutrients $x MED00189563
GRA    __
$a NU21-02-00135 $p Czech Health Research Council
GRA    __
$a SVV 260 549 $p Charles University
GRA    __
$a UHHK, 00179906 $p MH CZ - DRO
LZP    __
$a Pubmed-20230718
Back

Find record

Citation metrics

Archiving options